CD274 and non-small cell lung carcinoma: In our study, we reported data about serum cEVs and their miRNAs in a specific cohort of untreated patients with advanced stage (IIIB/IV) NSCLC at diagnosis, having PD-L1 immunohistochemical expression >50%, a median of two metastatic sites and eligible for first-line monotherapy with anti-PD-1, pembrolizumab.